ccRCC is an immunotherapy-sensitive tumor, and mTOR regulates tumor immunity (Posadas, Limvorasak & Figlin, 2017; Saxton & Sabatini, 2017). This evidence concerns the gene MTOR and nonpapillary renal cell carcinoma.